DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis.

Author(s): Markham T, Rogers S, Collins P

Affiliation(s): City of Dublin Skin and Cancer Hospital, Hume St, Dublin 2, Ireland. trevormarkham@hotmail.com

Publication date & source: 2003-03, Arch Dermatol., 139(3):325-8.

Publication type: Clinical Trial; Randomized Controlled Trial

OBJECTIVE: To compare the efficacy of narrowband UV-B (TL-01) phototherapy with oral 8-methoxypsoralen photochemotherapy (8-MOP psoralen-UV-A [PUVA]) in patients with chronic plaque psoriasis (CPP). DESIGN: Open, randomized, controlled study. SETTING: Phototherapy unit in a dermatology hospital. PATIENTS: Fifty-four patients with CCP. INTERVENTIONS: Patients received whole-body threshold erythemogenic dose of either 3-times weekly TL-01 or twice-weekly oral 8-MOP PUVA, based on minimal erythema or phototoxic doses. Patients were treated until completely clear. OUTCOME MEASURES: Number of treatments to clear, number of days in treatment, number of days in remission, and adverse effects of both therapies were assessed. RESULTS: Forty-five patients completed the study. Those in the PUVA group required significantly fewer treatments to clear (P =.03). There was no significant difference in the number of days to clear or number of days in remission. A similar percentage of patients in the TL-01 and PUVA groups developed minimal perceptible erythema, showing that the regimens were equally erythemogenic. Asymptomatic, well-defined erythema occurred only in the PUVA group. Pruritus and polymorphic light eruption occurred equally in both groups, but only patients in the PUVA group developed nausea. CONCLUSION: Narrowband UV-B phototherapy, used 3 times weekly, is as effective for the treatment of CPP as oral 8-MOP PUVA used twice weekly.

Page last updated: 2006-02-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012